With a market capitalization (market cap) of $128.1B — a measure of how much the company is worth — Vertex Pharmaceuticals Incorporated ranks #119 among the 2,510 companies tracked, and 16th in Healthcare as of October 2, 2026. Shares trade at $504.73, down 0.40% on the day.
of 2,510 tracked
Market-cap change uses historical capitalization records. Share-price returns are a different series — they can diverge when the share count changes. Those returns are not a CAGR until you pick a start value, an ending value, and years. CAGR calculator. Market cap vs. stock price.
Year-end values and the chart both come from historical market-cap records, not from applying today's share count to past prices. Latest historical observation October 2, 2026. Ranking headline cap is the snapshot figure as of October 2, 2026.
| Year | As of | Market cap | Annual change | Year-end close |
|---|---|---|---|---|
| 2026 | Oct 2, 2026 | $128.15B | +11.24% | $504.73 |
| 2025 | Dec 31, 2025 | $115.2B | +11.35% | $453.36 |
| 2024 | Dec 31, 2024 | $103.45B | -1.34% | $402.70 |
| 2023 | Dec 29, 2023 | $104.86B | +41.34% | $406.89 |
Ranking figure $128.1B as of October 2, 2026.
Vertex Pharmaceuticals Incorporated's ranking market cap is the provider-reported capitalization on the same snapshot as the rest of this site, with a share price of $504.73 as of October 2, 2026. Charts and the year-end table use a separate historical market-cap series, last observed at $128.15B on October 2, 2026. See how the ranking works.
Live shares outstanding are not on the quote used for price, so this page does not invent a current share count. Shares outstanding vs. float.
The latest annual report (FY 2025) used a weighted-average 255,700,000 shares. That figure is an average for the year, not the live count in the market-cap formula.
Book equity: assets minus liabilities on the latest annual report.
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Not in this snapshot
FY 2025 net worth
Largest U.S.-listed names in the same FMP sector — not a hand-picked competitor set.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #14 | Eli Lilly and Company LLY | $1.08T | -0.61% |
| #21 | Johnson & Johnson JNJ | $617.01B | -1.02% |
| #24 |
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation.
Summary from the company profile (Financial Modeling Prep). Principal financial figures above are for FY 2025.
Visit websiteAs of October 2, 2026, Vertex Pharmaceuticals Incorporated (VRTX) is worth $128.1B — that is its market capitalization, the total value of its outstanding shares on MarketCapLens.
A company’s net worth is its shareholders’ equity: assets minus liabilities on the balance sheet. That is book equity, not market cap. For FY 2025, Vertex Pharmaceuticals Incorporated’s book equity is about $18.67B. Market cap is the market value of the outstanding shares. As of October 2, 2026, its market cap is $128.1B. Book equity is an accounting remainder; market cap is a trading value. Neither is a person’s net worth.
Vertex Pharmaceuticals Incorporated ranks #119 among the 2,510 companies tracked on MarketCapLens. In Healthcare it ranks #16 of 350.
Fundamentals are annual. Figures labeled with their fiscal year. Live ratios use the current price against those annual earnings.
| 2022 |
|---|
| Dec 30, 2022 |
| $74.19B |
| +32.43% |
| $288.78 |
| 2021 | Dec 31, 2021 | $56.02B | — | $219.60 |
|---|
Last observation of each calendar year from historical market-cap records. The current year is through the latest date, not a completed year-end. Share-price close is the matching session for context — we do not rebuild cap from today's share count.
Not in this snapshot
FY 2025
| $464.35B |
| +1.11% |
| #36 | Merck & Co., Inc. MRK | $356.4B | +0.34% |
| #38 | UnitedHealth Group Incorporated UNH | $337.74B | +1.83% |
| #52 | Novartis AG NVS | $268B | -0.04% |
Companies immediately above and below in the overall ranking. They may be in a different sector.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #116 | Fortinet, Inc. FTNT | $132.77B | +1.25% |
| #117 | Mizuho Financial Group, Inc. MFG | $132.66B | +1.21% |
| #118 | Unilever PLC UL | $128.61B | +0.20% |
| #120 | Chubb Limited CB | $127.66B | -0.12% |
| #121 | Bristol-Myers Squibb Company BMY | $124.91B | -0.50% |
| #122 | Cloudflare, Inc. NET | $123.86B | -0.58% |
Vertex Pharmaceuticals Incorporated’s ranking market cap of $128.1B comes from the same snapshot as the rest of this site, as of October 2, 2026. It is not share price multiplied by the FY 2025 weighted-average share count of 255,700,000. The historical market-cap series last observed $128.15B on October 2, 2026.
Over the past year, Vertex Pharmaceuticals Incorporated’s market cap is up 23.45%, using historical market-cap records rather than today’s share count applied to past prices.
Vertex Pharmaceuticals Incorporated (VRTX) shares trade at $504.73, down 0.40% on the day, as of October 2, 2026.
Vertex Pharmaceuticals Incorporated trades at a live price-to-earnings (P/E) ratio of 32.6, using the latest share price divided by the latest annual earnings per share. That is not the same as a fiscal-year reported P/E.